— Presentation on September 18, 2015, at 9:45 a.m. GMT —
BRISBANE, Calif.--(BUSINESS WIRE)--Sep. 2, 2015--
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company
developing desensitization treatments for food allergies, today
announced that it will present at the Bank of America Merrill Lynch
Global Healthcare Conference in London.
About the Presentation
Friday, September 18, 2015, at 9:45 a.m. GMT
The live audio webcast of the presentation can be accessed from the
Investor Relations section of the company’s website at www.aimmune.com.
A replay will be available for 14 days following the presentation.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc., founded in 2011 as Allergen Research
Corporation (ARC), is a clinical-stage biopharmaceutical company
developing treatments for peanut allergy and other food allergies.
Aimmune Therapeutics’ characterized oral desensitization immunotherapy
(CODIT™) system, an approach to oral immunotherapy (OIT), uses
rigorously characterized product candidates with gradual, controlled
up-dosing protocols to obtain clinically meaningful desensitization to
food allergens. Aimmune Therapeutics recently completed a Phase 2 study
of its lead product, AR101, a complex mixture of naturally occurring
proteins and pharmaceutical-grade ingredients for the treatment of
peanut allergy, one of the most common food allergies. For more
information, please see www.aimmune.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150902006252/en/
Source: Aimmune Therapeutics, Inc.
Aimmune Therapeutics, Inc.
Amy Figueroa, 650-352-1039 (Investors)
Breeding, 415-229-7649 (Media)